Jubilant

Articles

Vetting a CMO for sterile injectable fill finish means more than capacity and equipment. This white paper from Jubilant HollisterStier discusses the range of factors to consider when outsourcing manufacturing for aseptically filled and terminally sterilized products.

Selecting a CMO Partner for Sterile Injectable Manufacturing (Nov 2023)

There are many reasons behind the success of a technology transfer. But at the center of this complexity is one critical role: project management in the tech transfer.

Project Management: The Secret Weapon in Effective Tech Transfer (Oct 2023)

Central to a successful technology transfer is effective project management. This white paper discusses the role of project management at Jubilant HollisterStier in creating and executing transfer plans and the innovative solutions developed for the transfer of five COVID-19 vaccine and therapeutic fill finish manufacturing projects.

Project Management: The Secret Weapon in Effective Tech Transfer

Selecting a CMO Partner for Sterile Injectable Manufacturing (Oct 2023)

Specialization in ophthalmic manufacturing, demonstrated by investment in equipment, technical project management, quality systems, and regulatory compliance, ensures a safe, effective eyecare drug product. Learn what to look for in a contract manufacturing organization for ophthalmic fill finish, and how Jubilant HollisterStier can validate and scale highly efficient, replicable processes.

Achieving Ophthalmic Production with Jubilant HollisterStier

In this Drug Digest video, our speakers will discuss CDMOs and their ever-changing role in the biopharma space and current barriers in cell and gene therapy (CGT) manufacturing. Join the Drug Digest video to help prepare for manufacturing and cell/gene therapy challenges. Learn how digitalization, CDMOs, and CGT relate to conventional biopharma development and manufacturing.

https://www.pharmtech.com/pt_w/accelerating-biopharma

The biopharmaceutical industry has seen a lot of change in recent years, between new collaborations with supplier and contract development and manufacturing organizations (CDMOs) and accelerated drug delivery times. According to recent research, biopharmaceutical figures are already using digital and analytics for their benefit, with an increase of up to 40% in plant capacity, 20% in lead time, and 15% reduction in conversion costs (1).


With more growth comes more responsibilities, and processes like cell and gene therapy are on the forefront for the latest strategies to overcome the challenges in the manufacturing space.
In this Drug Digest video, Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, and Jason C. Foster, CEO and executive director at Ori Biotech, will provide expert insights into what happens in the manufacturing space from a CDMO and a cell/gene therapy perspective.

Reimagining the future of biopharma manufacturing

. October 11, 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-the-future-of-biopharma-manufacturing

The ability to identify the benefits of biopharma companies partnering with a CDMO

The ability to learn about different kinds of cell and gene therapies and how to overcome the barriers in the continuous manufacturing space

Problem solving: ability to develop a plan for concepts, such as scalability and being more cost efficient, with new products and techniques

Awareness: ability to successfully pinpoint new approaches to medicine and how to respond as a biopharma company


Global Head of Technical and Scientific Affairs
Pharma Services at Thermo Fisher Scientific

Webcasts

Webinar Date/Time: Thu, Jul 20, 2023 11:00 AM EDT
